当前位置: X-MOL首页全球导师 国内导师 › 廖晨钟

个人简介

工作经历 2012/10-至今,合肥工业大学,生物与医学工程学院,教授 2010/10-2012/9,University of Michigan,Medical School,Research Scientist 2005/10-2010/9,National Institutes of Health,National Cancer Institute,博士后 2004/7-2005/8,深圳微芯生物科技有限责任公司,生化信息学部,主任 1998/7-2001/8,北京工业大学出版社,图书编辑 教育经历 2001/9–2004/7,中国科学院,博士 1995/9–1998/6,北京工业大学,硕士 1991/9–1995/7,青岛科技大学,学士

研究领域

药物设计、药物合成、新药研发、化学信息学 1、药物设计与合成 2、计算机辅助药物设计 3、化学信息学 4、恶性肿瘤药物、神经退行性疾病药物、抗艾滋病药物的研发

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Developing Polo-Like Kinase 1 Inhibitors. Future Medicinal Chemistry, 2020, 12, 869-871.(通讯作者) Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. Bioorganic & Medicinal Chemistry Letters, 2020, 30, 127036.(通讯作者) Discovery and development of plasma kallikrein inhibitors for multiple diseases. European Journal of Medicinal Chemistry, 2020,190, 112137.(通讯作者) Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library. European Journal of Medicinal Chemistry, 2020,189, 112023. Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. Journal of Medicinal Chemistry, 2020,63, 2489-2510. LongShengZhi Capsule Inhibits Doxorubicin-Induced Heart Failure by Anti-Oxidative Stress. Biomedicine & Pharmacother, 2020, 123, 109803. Discovery of Class I Histone Deacetylase Inhibitors Based on Romidpesin With Promising Selectivity for Cancer Cells. Future Medicinal Chemistry, 2020, 12, 311-323. Structure-based Design and SAR Development of Novel Selective Polo-Like Kinase 1 Inhibitors Having the Tetrahydropteridin Scaffold. European Journal of Medicinal Chemistry, 2019, 184, 111769.(通讯作者) Developments in Inhibiting Platelet Aggregation Based on Different Design Strategies. Future Medicinal Chemistry, 2019, 11, 1757-1775.(通讯作者) Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors. Current Medicinal Chemistry, 2019, DOI: 10.2174/0929867326666190402110528. Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure. Bioorganic & Medicinal Chemistry Letters, 2019, 29, 1012-1018.(通讯作者) Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors. Bioorganic & Medicinal Chemistry Letters, 2019, 29, 1090-1093.(通讯作者) Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Scientific Reports, 2018, 8, 10210.(并列第一作者) The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. European Journal of Medicinal Chemistry, 2018,146, 299-317.(通讯作者) Design, Synthesis and Bioevalucation of Novel 2,3-Dihydro-1H-inden-1-amine Derivatives as Potent and Selective Human Monoamine Oxidase B Inhibitors Based on Rasagiline. European Journal of Medicinal Chemistry, 2018,145, 588-593.(通讯作者) Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold. European Journal of Medicinal Chemistry, 2018,143, 724-731.(通讯作者) Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer. Current Medicinal Chemistry,2017, 24, 4166-4179.(通讯作者) nhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. ACS Chemical Biology. 2017, 12, 724-734. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. Journal of Medicinal Chemistry, 2016, 59, 5766-5779.(并列第一作者) From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036.(通讯作者) Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors. Bioorganic & Medicinal Chemistry,2016, 24, 1741-1748.(通讯作者) Identification of human telomerase inhibitors having the core of N-acyl-4,5-dihydropyrazole with anticancer effects. Bioorganic & Medicinal Chemistry Letters,2016, 26, 1508-1511.(通讯作者) Chemical Structure Similarity Search for Ligand-Based Virtual Screening: Methods and Computational Resources. Current Drug Targets. 2016, 17, 1580 - 1585. Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step? Current Topics in Medicinal Chemistry. 2016, 16, 467-469.(通讯作者) Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in vitro and in vivo Antitumor Activities. Journal of Medicinal Chemistry, 2015, 58, 7672-7680. Metalloprotein Inhibitors for the Treatment of Human Diseases. Current Topics in Medicinal Chemistry, 2016, 16, 384-396.(通讯作者) Editorial: Current Progress in the Development of Metalloprotein Inhibitors. Current Topics in Medicinal Chemistry, 2016, 16, 383.(通讯作者) Novel HIV-1 Integrase Inhibitor Development by Virtual Screening Based on QSAR Models. Current Topics in Medicinal Chemistry, 2016, 16, 441-448. Ma N, Luo Y, Wang Y, Liao C, Ye WC, Jiang S. Selective histone deacetylase inhibitors with anticancer activity. Current Topics in Medicinal Chemistry, 2016, 16, 415-426. Novel 2H-chromen-2-one Derivatives of Resveratrol: Design, Synthesis, Modeling and Use as Human Monoamine Oxidase Inhibitors. European Journal of Medicinal Chemistry, 2015,103, 185-190.(通讯作者) Synthesis, Characterization and Antitumor Activity of Novel Ferrocene-Based Amides Bearing Pyrazolyl Moiety. Journal of Inorganic and Organometallic Polymers and Materials, 2015, 25, 419-426. Discovery and Pharmacophore Studies of Novel Pyrazole-Based Anti-Melanoma Agents. CHEMISTRY & BIODIVERSITY, 2015, 12, 116-132.(通讯作者)

推荐链接
down
wechat
bug